Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of two Phase IIi Randomized Controlled Trials
Lebwohl, M.G..; Sugarman, J.L..; Stein Gold, L.; Lin, T.; Israel, R.
Journal of Drugs in Dermatology Jdd 18(10): 1012-1018
2019
ISSN/ISBN: 1545-9616 PMID: 31584780 Document Number: 17967
Background: The use of topical therapy is a key component in the management of almost all psoriasis patients. Topicals are considered first-line therapy for mild disease and are having an increasing role in moderate or severe psoriasis as an integral part of combination therapy. Halobetasol has been shown be effective in moderate or severe localized plaque psoriasis, and tazarotene affords important effects on epidermal hyperproliferation that may be important in more severe disease.
Document emailed within 1 workday
